Новый альтернирующий режим при метастатическом почечно-клеточном раке на примере клинического случая
Maria S. Sayapina, С. В. Ширяев, Alexander S. Krylov et al. · CyberLeninK (CyberLeninka) · 2016
In the article a new alternating regimen which includes alternation between interferon (INF) immunotherapy and target therapy (sunitinib) is described through a clinical case. Mentions of this type of regimen weren’t found in the literature. As a result of the regimen, treatment efficacy increased due to decreased development of resistance to targeted therapy, cumulative toxicity decreased, synergy between immunotherapy and targeted therapy was achieved, and the cost of the treatment was reduced by 50 %. Considering the above, other alternating regimens can be of interest for researchers: INF/targeted therapies (INF/axitinib, et al.), checkpoint inhibitors/targeted therapies. At the same time, randomized phase II trial ROPETAR showed that alternation of targeted therapies (pazopanib/everolimus) does not increase treatment efficacy or decrease toxicity in comparison with sequential dosing.
Cited by 0 works.